{
    "nctId": "NCT01173341",
    "briefTitle": "Cardiotoxicity of Cancer Therapy (CCT)",
    "officialTitle": "Cardiotoxicity of Cancer Therapy: Mechanisms and Predictors",
    "overallStatus": "ENROLLING_BY_INVITATION",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 700,
    "primaryOutcomeMeasure": "Cardiac dysfunction or signs or symptoms of heart failure",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age 18 years or older\n* HER-2 positive breast cancer designated to receive trastuzumab chemotherapy with or without prior exposure to anthracycline-based chemotherapy\n* Non-HER-2 positive breast cancer designated to receive treatment with an anthracycline-containing regimen\n\nExclusion Criteria:\n\n* Pre-existing cardiomyopathy with a left ventricular ejection fraction of less than 50%.\n* Other contraindications to trastuzumab or anthracycline chemotherapy.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}